What the business is, and whether it's a good one at a fair price.
Runs two business segments - Pharmaceuticals and Electronics - through group companies, generating consolidated revenue of Rs 202.27 crore in FY26. The Pharmaceuticals business is operated through Asence Pharma and the Electronics business through Systronics India, with Synbiotics as an additional group entity; both segments reported positive EBIT in FY26. Electronics was the faster-growing of the two in Q3 FY26, growing about 34% year-on-year while Pharmaceuticals stayed largely flat. On the cost side, raw materials are only 9.5% of revenue while employees absorb 16.1% and other operating expenses 19.2%, indicating limited direct commodity exposure. Depreciation of 1.9% and capex of 2.1% of revenue point to a low capital-intensity operating model.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from AMBALAL SARABHAI ENT L's filed financials and exchange disclosures
AMBALAL SARABHAI ENT L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AMBALALSA.
Yes. Over the trailing twelve months AMBALAL SARABHAI ENT L reported a net profit of ₹18 Cr on revenue of ₹202 Cr.
Not in the latest reported year — AMBALAL SARABHAI ENT L's dividend payout for FY26 was nil.
No. Debt stands at 0.33× equity, and it carries net debt of ₹45 Cr. That is lower than 28% of its 171 Pharmaceuticals peers.
On trailing P/E, AMBALAL SARABHAI ENT L ranks 47 of 169 in Pharmaceuticals — cheaper than 73% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session AMBALAL SARABHAI ENT L moves 2.07% — that is the median absolute close-to-close move across its last 100 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by AMBALAL SARABHAI ENT L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
